medigraphic.com
ISSN 1560-4381 (Print)

2013, Number 4

<< Back Next >>

Correo Científico Médico 2013; 17 (4)

Neoadjuvant chemotherapy in locally advanced breast cancer

Portelles CA, Rodríguez AY, Fernández SPA, Sanz PNJ, Oller PJ

Language: Spanish
References: 30
Page: 433-442
PDF size: 153.73 Kb.


ABSTRACT

Introduction: breast cancer is the most common malignant tumor in women at this moment. Chemotherapy is one of the main therapeutic tools against this pathology.
Objective: characterize the behavior of patients with local advanced breast cancer who recieved neoadyuvant chemotherapy at Holguín Oncological Center from January 2010 to December 2011.
Methods: a prospective and descriptive study was carried out. All patients with breast cancer were the universe and the sample comprised 87 patients who completed all the treatment.
Results: women were the predominant gender (96.56%) as well as the age group between 40-49 years (35.63%). Doxorubicin with Cyclophosphamide treatment prevailed (44.83%) and 37.93% of these patients received four cycles of it. The toxicity by chemotherapy did not interfere in this therapy and nauseas with or without vomiting was the most frequent adverse reaction (90.80%). Most patients assimilated the treatment partially 55.17% of them. Thus, with this treatment there was a partial recovery in the majority of patients and the toxicity did not delay the therapy.
Conclusions: locally advanced breast cancer could be found commonly in 40-49 years old women. Chemotherapy schedule more frequently used was the junctions of doxorubicin and cyclophosphamide, reaching a partial response in the majority number of patients and the toxicity never delay the therapy.


REFERENCES

  1. Gutiérrez J. Terapia sistémica neoadyuvante en cáncer de mama. Rev Med Clin Condes. 2006; 17(4): 216–20.

  2. Andreu FJ. Neoadyuvancia en cáncer de mama. Marcadores predictivos y pronóstico. XXXI Reunión Anual SEAP-DEAIP Madrid, 7-8 de febrero de 2008.España: Panamericana; 2008.

  3. Chile. Ministerio de Salud Pública. Registro Notificación Unidad de Cáncer. Chile: Editorial Ministerio de Salud Pública; 2003.

  4. Cuba. Ministerio de Salud Pública. Registro de Estadística Nacional. Comportamiento del cáncer de mama. La Habana: Editorial Ministerio de Salud Pública; 2010.

  5. Harris JR, Lippman ME, Veronesi U. Breast cancer. N Engl J Med.1992; 327:319-5.

  6. Van der Hage JA, Van de Velde CJ, Julien JP. Tubiana-Hulin in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.J Clin Oncol. 2001; 19(22): 4224–7.

  7. Vaqar Mustafa A. Cancer Chemoprevention by Pomegranate: Laboratory and Clinical Evidence. Nutrition Cancer. 2009; 61(6): 811–5.

  8. Fernández Pérez I. Oncomecum. (CD-ROM). España: Publicaciones Permayer; 2005.

  9. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the scienceconcerning locoregional treatments after preoperative chemotherapy for breastcancer: a National Cancer Institute conference. J Clin Oncol. 2008; 26 (5), 791–7.

  10. Andreu FJ. Neoadyuvancia en cáncer de mama. Marcadores predictivos y pronóstico. XXXI Reunión Anual SEAP-DEAIP Madrid, 7-8 de febrero de 2008.Madrid: España; 2008.

  11. Hidalgo A. Cáncer de mama en México: una prioridad apremiante. Salud pública Méx. 2009 [citado 12 oct 2012]; 51.

  12. Regaño S. Oncoplstic Techniques Extended Breast Suurgery to patienrs with Neoadjuvant Chemiothreapy Response Unfet for Convencional Techniques. World J Surg. 2009; 33:2082–6.

  13. Wolmark N. Effect of preoperative chemotherapy on G3 the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16:2672-5.

  14. Alborado A. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiat Oncology. 2009; 4:24.

  15. Vera B. Respuesta clínicos y patológicos a la quimioterapia neoadyuvante en pacientes con cáncer de mama etapa clínica III. 2008 [citado 12 oct 2013].

  16. Oliva A, Gilberto Morgan V, Castro Cervantes JM, Vázquez Camacho G, Fuentes Orozco C, González Ojeda A. Tratamiento neoadyuvante del cáncer de mama localmente avanzado. Comparación de dos esquemas a base de docetaxel-epirrubicina versus 5-fluoracilo-epirrubicina-ciclofosfamida. Cir Ciruj. 2008; 76 (1): 22-9.

  17. Vicente Plaa EB, Manuel Muñoza CF, Safonta MF, Vicente Ginera AG, Vicente Roig J. Tratamiento quirúrgico tras quimioterapia neoadyuvante en el cáncer de mama operable: once años de experiencia. Cir Esp. 2003; 74(6):325-9.

  18. Cheving Tanfo T. Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers? ANZ J Surg. 2009; 79(10):719-23.

  19. Straver ME. The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy. Ann Surg Oncol. 2010; 17:2411–8.

  20. Insa A. Tratamiento neoadyuvante del cáncer de mama operable. Hospital Clínico Universitario de Valencia. Med Clin. 2006; 126(8):133-41.

  21. Camacho R, Rubio MC, Rodríguez R, Pérez Braojo I, Valdés Pozo Z, Sánchez Varelo I, et al. Sociedad Valenciana de Cirugía. Guías de diagnóstico y tratamiento en cáncer de mama. España: Sociedad Valenciana de Cirugía. 2007[citado 12 oct 2012].

  22. Smith I, Procter M, Gelber RD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007; 369(9555):29–36.

  23. Evans A. Quality Assessment of Neoadjuvant Therapy Use in Breast Conservation: Barriers to Implementation. The Breast J. 2009; 15 (5): 524–6.

  24. Gogas H. Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. Clinical Breast Cancer.2010; 10(3):230-7.

  25. Robin LJ, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010; 119:315–3.

  26. Bryski T. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009; 115:359–3.

  27. Dose J. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. British J Cancer.2010; 102, 35 – 41.

  28. Denice Y. A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients with Locally Advanced or Inflammatory Breast Cancer. Clinical Breast Cancer. 2010; 10 (3): 217-3.

  29. Robidaux A. A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer. Clinical Breast Cancer. 2010; 10 (1): 81-6.

  30. Hirata H. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. British J Cancer. 2009; 101: 1529–6.




2020     |     www.medigraphic.com